Michael Megna
Comptroller/Controller/Auditor at KINIKSA PHARMACEUTICALS, LTD.
Net worth: 420 801 $ as of 2024-03-30
Profile
Michael R.
Megna is currently the Chief Accounting Officer & Vice President-Finance at Kiniksa Pharmaceuticals Ltd.
He previously worked as the Chief Accounting Officer & Corporate Controller at BioSphere Medical, Inc. from 2004 to 2010.
He also held the position of Senior Vice President-Finance & Accounting at LFB USA, Inc. Mr. Megna completed his undergraduate degree at Siena College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-04-07 | 21,328 ( 0.05% ) | 420 801 $ | 2024-03-30 |
Michael Megna active positions
| Companies | Position | Start |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Comptroller/Controller/Auditor | 2020-02-03 |
Former positions of Michael Megna
| Companies | Position | End |
|---|---|---|
BioSphere Medical, Inc.
 BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | Comptroller/Controller/Auditor | 2010-10-31 |
LFB USA, Inc.
 LFB USA, Inc. Pharmaceuticals: MajorHealth Technology LFB USA, Inc. is a pharmaceutical company based in Framingham, MA. The private company develops and provides pharmaceutical bioproducts through innovative technologies for patients with serious diseases. LFB USA is committed to improving people's lives by overcoming barriers through purposeful science. The company offers a robust set of services that powers its own pipeline to its partners. LFB USA's rpro technology is revolutionizing recombinant protein production for a new generation of therapeutics. The company is ultimately controlled by the Government of France. Jose Antonio Moreno Toscano has been the CEO of the company since 2018. | Comptroller/Controller/Auditor | - |
Training of Michael Megna
| Siena College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| Private companies | 2 |
|---|---|
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | Health Technology |
LFB USA, Inc.
LFB USA, Inc. Pharmaceuticals: MajorHealth Technology LFB USA, Inc. is a pharmaceutical company based in Framingham, MA. The private company develops and provides pharmaceutical bioproducts through innovative technologies for patients with serious diseases. LFB USA is committed to improving people's lives by overcoming barriers through purposeful science. The company offers a robust set of services that powers its own pipeline to its partners. LFB USA's rpro technology is revolutionizing recombinant protein production for a new generation of therapeutics. The company is ultimately controlled by the Government of France. Jose Antonio Moreno Toscano has been the CEO of the company since 2018. | Health Technology |
- Stock Market
- Insiders
- Michael Megna
